Sixth International Prostate Cancer Symposium & World Congress of Urologic Oncology

Wednesday, December 11, 2024, 7:00 AM - Saturday, December 14, 2024, 6:30 PM, Mount Sinai Hospital, New York, NY


Be at the forefront of cutting-edge techniques and innovation in urology and robotic surgery. Prostate, Kidney and Bladder Cancer along with Basic Science talks and presentations, live surgeries, 3D video presentations, simulation laboratories and more. In New York City, Dec 11-14, 2024. A long line up of over 80 world-renowned speakers, who are leaders in the field and opportunity to learn from and connect with them.

1. Utilize evidence based screening and diagnostic techniques for prostate cancer more efficiently.
2. Discuss effective management of treatment failure in prostate cancer to help reduce mortality.
3. Describe the most recent approach to treating locally advanced and metastatic urologic disorders.
4. Identify the technical challenges of robotic urologic oncologic surgery

All refund and cancellation requests must be emailed to the CME office at [email protected] by December 1, 2024. Cancellations after this date are not eligible for a refund. An administrative fee of $50 will be deducted from your refund. No refunds will be issued for registration fees that are equal to or less than $50.00. No refunds will be issued for “no-shows.”

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (34.00 hours), Non-Physician Attendance (34.00 hours)

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

Icahn School of Medicine at Mount Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.